An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
OBJECTIVE
In this study we describe a newly established CD30+ Epstein Barr virus (EBV)-infected B cell line derived from an EBV-infected B cell culture (utilized, once irradiated, as a feeder) which showed a B clonal rearrangement and strong CD30 antigen expression.


METHODS
The cells injected into SCID mice were able to grow giving rise to CD30+ solid tumors with the morphologic features of an anaplastic large cell lymphoma (ALCL). Thus we tried to establish a model to investigate the potency of immunoconjugates containing a CD30 monoclonal antibody (Ber-H2) and ribosome-inactivating proteins (saporin, momordin and ricin A-chain) as toxic moieties.


RESULTS
We observed a strong cytotoxic activity of the anti-CD30 immunotoxins on the in vitro growth of D430B cells. High levels of anti-tumor activity were also observed in vivo, in the SCID mouse model.


CONCLUSIONS
The antitumor immunotoxin therapy was sccessful in our chosen animal model, the effecacy seeming to be associated with strength of CD30 expression. Our data suggest that immunotoxins should be tested (before use) on the tumor cells of the subject to be treated and that immunotoxins should be directed to different tumor-associated antigens to avoid selection of cell populations with different antigenic mosaics.
Tazzari
P L
PL
Servizio di Immunoematologia e Trasfusionale, Policlinico S.Orsola, Bologna, Italy.
de Totero
D
D
Bolognesi
A
A
Testoni
N
N
Pileri
S
S
Roncella
S
S
Reato
G
G
Stein
H
H
Gobbi
M
M
Stirpe
F
F
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D004195:Disease Models, Animal; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology*; D007150:Immunohistochemistry; D000922:Immunotoxins / Q000627:therapeutic use*; D007621:Karyotyping; D008099:Liver / Q000473:pathology; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D051379:Mice; D016513:Mice, SCID; D009699:N-Glycosyl Hydrolases; D010179:Pancreas / Q000473:pathology; D010940:Plant Proteins / Q000627:therapeutic use; D054789:Ribosome Inactivating Proteins, Type 1; D054790:Ribosome Inactivating Proteins, Type 2; D012276:Ricin / Q000627:therapeutic use; D000076985:Saporins; D013154:Spleen / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000276:immunology
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000922:Immunotoxins; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D054790:Ribosome Inactivating Proteins, Type 2; D012276:Ricin; D009699:N-Glycosyl Hydrolases; D000076985:Saporins